Poolbeg Pharma plc completed a successful, upsized and oversubscribed fundraising to raise total gross proceeds of £4.865 million Poolbeg Pharma conditionally raised £4.865 million following the placing of 134.8 million new Ordinary Shares, raising gross proceeds of £3.370 million, the subscription of 53.8 million new Ordinary Shares, raising gross proceeds of £1.345 million, and an […]
Mapping out the top life science conferences to attend in the next six months Will we see you there? The Optimum team has taken a moment to map out the top life science conferences to attend in the next six months. As an official partner to many of the top events, Optimum is pleased to […]
Great news from the European Congress on Obesity (ECO) in Malaga earlier this week: obesity drugs such as Wegovy and Mounjaro slash the chances of dying from a range of killer diseases including strokes, heart attacks and various cancers. Roughly speaking, they halve the risk. GLP-1s appear to “affect the biology of diseases of ageing”, […]
Kaerus Bioscience’s lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS) Kaerus Bioscience announces that its lead candidate KER-0193 has been granted both Orphan Drug and Rare Pediatric Drug Designations for the treatment of Fragile X syndrome (FXS) by the U.S. Food […]
Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company Alchemab Therapeutics announced that it has entered into a $415m licensing agreement with Eli Lilly and Company for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. ATLX-1282 is the first programme out of Alchemab’s entirely […]
